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Articles
Eﬀ ect of mass paediatric inﬂ uenza vaccination on existing 
inﬂ uenza vaccination programmes in England and Wales: 
a modelling and cost-eﬀ ectiveness analysis
David Hodgson, Marc Baguelin, Edwin van Leeuwen, Jasmina Panovska-Griﬃ  ths, Mary Ramsay, Richard Pebody, Katherine E Atkins
Summary
Background In 2013 England and Wales began to fund a live attenuated inﬂ uenza vaccine programme for individuals 
aged 2–16 years. Mathematical modelling predicts substantial beneﬁ cial herd eﬀ ects for the entire population as 
a result of reduced inﬂ uenza transmission. With a decreased inﬂ uenza-associated disease burden, existing 
immunisation programmes might be less cost-eﬀ ective. The aim of this study was to assess the epidemiological eﬀ ect 
and cost-eﬀ ectiveness of the existing elderly and risk group vaccination programme under the new policy of mass 
paediatric vaccination in England.
Methods For this cost-eﬀ ectiveness analysis, we used a transmission model of seasonal inﬂ uenza calibrated to 14 seasons 
of weekly consultation and virology data in England and Wales. We combined this model with an economic evaluation 
to calculate the incremental cost-eﬀ ectiveness ratios, measured in cost per quality-adjusted life-years (QALY) gained.
Findings Our results suggest that well timed administration of paediatric vaccination would reduce the number of 
low-risk elderly inﬂ uenza cases to a greater extent than would vaccination of the low-risk elderly themselves if the 
elderly uptake is achieved more slowly. Although high-risk vaccination remains cost-eﬀ ective, substantial uncertainty 
exists as to whether low-risk elderly vaccination remains cost-eﬀ ective, driven by the choice of cost-eﬀ ectiveness 
threshold. Under base case assumptions and a cost-eﬀ ectiveness threshold of £15 000 per QALY, the low-risk elderly 
seasonal vaccination programme will cease to be cost-eﬀ ective with a mean incremental cost-eﬀ ectiveness ratio of 
£22 000 per QALY and a probability of cost-eﬀ ectiveness of 20%. However, under a £30 000 per QALY threshold, the 
programme will remain cost-eﬀ ective with 83% probability.
Interpretation With the likely move to decreased cost-eﬀ ectiveness thresholds, reassessment of existing risk 
group-based vaccine programme cost-eﬀ ectiveness in the presence of the paediatric vaccination programme is needed.
Funding National Institute for Health Research, the Medical Research Council.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Individuals at high risk of serious complication after an 
inﬂ uenza infection have historically been the target for 
seasonal inﬂ uenza annual vaccination programmes 
worldwide.1–3 However, because of the indirect eﬀ ects of 
vaccination, termed herd protection, the vaccination of 
groups who are important for transmission of infection is 
often also cost-eﬀ ective.4,5 A large proportion of this 
transmission is attributable to children and adolescents 
because of the relatively high number of contacts they 
have with others,6–8 the fraction of these contacts that 
involve touching,6–8 and their susceptibility to inﬂ uenza 
infection.9,10 Some countries have broadened their seasonal 
inﬂ uenza vaccine recommendations to immunise healthy 
children and adolescents every year, for example in the 
USA11 and more recently in the UK in 2012.12,13
If paediatric immunisation programmes gain high 
coverage early enough in the inﬂ uenza season to interrupt 
transmission to risk groups, any existing risk group-based 
vaccine programme becomes less cost-eﬀ ective. If a 
national paediatric programme renders elderly and risk 
group vaccination programmes not cost-eﬀ ective, then 
removing annual vaccination from these target groups 
will allow a large annual saving. Previous analysis in the 
context of the UK suggests that substantial uncertainty 
exists regarding the cost-eﬀ ectiveness of an elderly 
low-risk programme in the presence of a moderate 
vaccine uptake of 50% in healthy children12,13 and 
adolescents, with a third of simulations ﬁ nding the 
elderly vaccine not to be cost-eﬀ ective.
To reduce seasonal inﬂ uenza-associated serious disease 
in elderly people and in individuals clinically at risk 
from inﬂ uenza-related disease, England and Wales are 
introducing a publicly funded universal funded paediatric 
vaccination programme,12,13 using live attenuated 
inﬂ uenza vaccine (LAIV). The LAIV programme began 
in 2013 and oﬀ ered the intranasal vaccines to all healthy 
children aged 2–3 years and to healthy children aged 4 
years and those in primary grades 1–6 (children 
commencing the school year aged 5–10 years) who were 
enrolled in a pilot study done in seven regions. In 
2014–15, the programme extended to all children aged 
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2–4 years, and the ongoing pilot studies expanded to 
include some regions oﬀ ering vaccines to secondary 
school-aged adolescents in school grades 7–8 (those 
commencing the school year aged 11–12 years). In 
2015–16, the programme oﬀ ered vaccines to primary 
grades 1–2 (those commencing the school year aged 
5–6 years) and continued to oﬀ er vaccines to children 
aged 2–4 years and children in the previous pilot areas. 
From 2016 onwards, the programme extends year on 
year to children in the rest of the primary school grades 
(aged 5–10 years when commencing the school year) and 
secondary school adolescents (aged 11–15 years when 
commencing the school year).14 Case-control studies have 
been implemented over this period to ascertain the direct 
eﬀ ectiveness across each season.15,16
Using England as a case study, we assess the likely 
eﬀ ect and cost-eﬀ ectiveness of the existing elderly and 
risk group vaccination programme under the new policy 
of mass paediatric vaccination. Speciﬁ cally, we assess 
whether maintaining a low-risk elderly and high-risk 
seasonal inﬂ uenza vaccination programme remains 
cost-eﬀ ective in the presence of preschool and 
school-based vaccination with varying vaccine coverages 
achieved at diﬀ erent speeds. Although the focus of our 
study assesses the situation after the decision in England 
in 2012 to introduce preschool-age and school-age 
inﬂ uenza vaccination, we extend this result to general 
policy considerations for other countries where paediatric 
programmes are currently under review.
Methods
Epidemiological eﬀ ect of paediatric vaccination
For this cost-eﬀ ectiveness analysis, to predict the direct 
and indirect eﬀ ects of seasonal inﬂ uenza vaccine 
programmes, we use a previously described transmission 
model of seasonal inﬂ uenza in England and Wales 
that is calibrated to 14 seasons of data.12,13 Using this 
calibrated model, we assessed the inﬂ uenza incidence in 
two groups: the high-risk population (individuals older 
than 6 months who have a diagnosed clinical disorder 
that puts them at risk of complications after inﬂ uenza 
infection); and the low-risk elderly population 
(individuals older than 64 years who are not categorised 
as high risk). We assess the inﬂ uenza incidence with 
and without low-risk elderly and high-risk vaccination, 
in the presence of three diﬀ erent paediatric programmes: 
(1) preschool age (2–4 years) only; (2) preschool and 
primary school age (2–10 years); and (3) preschool, 
primary, and secondary school age (2–16 years). Because 
children are known to be epidemiological drivers for 
seasonal inﬂ uenza transmission, the speed at which 
children are vaccinated will probably aﬀ ect the disease 
burden of the rest of the population. Therefore, we 
considered three administration speeds: (1) slow 
(uptake achieved between Jan 1 and Jan 31); (2) linear 
(uptake achieved between Oct 1 and Jan 31); and 
(3) fast (uptake achieved between Oct 1 and Oct 31). We 
also assessed the eﬀ ect of diﬀ erent paediatric vaccine 
coverages on the eﬀ ectiveness of the low-risk elderly and 
high-risk vaccine programmes.
Transmission model and LAIV assumptions
We use an age-speciﬁ c and risk-speciﬁ c mathematical 
model that captures seasonal inﬂ uenza transmission in 
England and Wales. The model is calibrated to the 
number of inﬂ uenza-like illness consultations and the 
frequency of virological conﬁ rmations from 1995 to 
2009. The calibrated model is parameterised with data 
on vaccination coverage, vaccine uptake speeds, and 
vaccine eﬀ ectiveness data for elderly and high-risk 
inactivated inﬂ uenza vaccination (IIV) in the absence of 
any paediatric vaccination. We calibrated the model 
using a Bayesian evidence synthesis approach, which 
captures uncertainty in the model parameters and is 
able to generate a distribution of model outcomes 
consistent with available data. The model captures the 
Research in context
Evidence before this study
Using a transmission model, our previous study showed that a 
paediatric vaccination programme can eﬀ ectively control 
seasonal inﬂ uenza because of the substantial herd protection 
conferred to unvaccinated children and adults. The decision to 
implement a paediatric vaccine programme in England was 
initiated after the evidence presented in a later study that 
combined the previous mathematical model with a 
cost-eﬀ ectiveness analysis. Although this study showed 
paediatric vaccination to be very cost-eﬀ ective, the study only 
superﬁ cially assessed the eﬀ ect of this programme on existing 
target group vaccination.
Added value of this study
In this Article, we assess the epidemiological eﬀ ect and 
cost-eﬀ ectiveness of the existing elderly and high-risk group 
vaccination in the presence of paediatric vaccination. Our study 
suggests that a mass paediatric vaccination programme will not 
aﬀ ect the existing recommendation of risk group vaccination in 
England. However, the continued cost-eﬀ ectiveness of a 
low-risk elderly vaccination programme is uncertain.
Implications of all the available evidence
This study highlights the importance of a cost-eﬀ ective 
paediatric vaccination scheme in curtailing inﬂ uenza 
transmission to the most vulnerable risk groups. However, 
important uncertainties exist surrounding the 
cost-eﬀ ectiveness of elderly programmes in the UK that might 
warrant reconsideration of this strategy in the coming years. 
We suggest that other countries introducing paediatric 
vaccination should reconsider their full vaccination schedule in 
view of these results. 
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dynamics of A/H1N1, A/H3N2, and B strains separately. 
In each year, IIV is either matched or unmatched to the 
circulating strain. IIV eﬃ  cacy was assumed to be 70% 
for people younger than 65 years and 46% for people 
aged 65 years or older for matched years, and 42% for 
people younger than 65 years and 28% for people aged 
65 years or older for unmatched years. More details on 
the model and model parameters have been published 
previously.12
After the calibration, we used the model to predict the 
distribution of elderly and high-risk inﬂ uenza cases 
averted in the presence of the new LAIV programme. In 
our base case scenario, we assumed LAIV eﬃ  cacy across 
all strains was equal to IIV eﬃ  cacy. Unless otherwise 
speciﬁ ed, our model was parameterised using the 
observed vaccine coverage and the speed of the uptake 
reported during the paediatric programme rollout for 
children aged 2–4 years and the pilot programme for 
children aged 4–16 years.17,18
Incremental cost-eﬀ ectiveness of the elderly 
vaccination programme
Extending the economic framework previously used for 
decision making on the paediatric programme in 
England,12,13 we assessed the net beneﬁ ts accrued from 
continuing both the low-risk elderly and high-risk 
annual inﬂ uenza vaccine programmes in England in 
the presence of a paediatric programme. We present the 
results in terms of the incremental cost for each 
quality-adjusted life-year gained (£ per QALY). For our 
base case analysis, we use 70% coverage for all children 
aged 2–16 years (consistent with uptakes in Scotland 
and Wales), together with the reported uptake speeds 
achieved in England for preschool-age children and 
school-age children (71% vs 40% achieved coverage by 
Oct 31, 89% vs 87% by Nov 30, and 94% vs 100% by 
Dec 31).18 For additional analyses, we also assessed the 
net beneﬁ ts achieved under a range of feasible paediatric 
vaccination coverages (status quo, 50%, and 90%), 
together with a fast administration of children and 
adolescents by the end of October.
Oﬃ  cially, for an intervention to be deemed cost-eﬀ ective 
in England, its incremental cost-eﬀ ectiveness ratio (ICER) 
must typically have been less than £20 000 per QALY, 
although interventions with ICERs less than £30 000 per 
QALY were also considered.19 The mean ICER and the 
probability that the ICER falls below these thresholds 
(ie, the probability of cost-eﬀ ectiveness) is also considered 
in the decision to fund a programme. Methodological 
research suggests that this threshold should be reduced 
to £13 000 per QALY20 and there is currently debate about 
whether the threshold will be updated.21 In practice, a 
threshold of about £15 000 per QALY would probably be 
deemed cost-eﬀ ective. With these issues in mind, we 
present the mean ICER, and cumulative probabilities for 
three thresholds: £15 000 per QALY, £20 000 per QALY, 
and £30 000 per QALY.
Economic evaluation assumptions
To calculate the cost-eﬀ ectiveness of the elderly 
programme and high-risk programmes, we integrated 
the transmission model into an economic evaluation. 
The economic evaluation tracks the number of general 
practitioner consultations, hospital admissions, and 
deaths for each year for the three strains. QALYs lost are 
assumed for febrile cases to have a mean of 7·49 × 10–³, 
and for cases admitted to hospital, to be normally 
distributed with a mean of 0·018 (SD 0·0018).13 Vaccine 
costs associated with vaccine price reimbursement and 
administration were triangularly distributed (£11·00, 
£15·55, £20·00). General practitioner and hospital 
treatment costs are assumed to be normally distributed 
with mean prices £37·00 (SD 8·40) and £839·00 
(192·10). Further details of the speciﬁ c health economic 
values used, including the health burden of each of 
the associated health outcomes has been previously 
published.13 No discounting was applied because the 
economic evaluation results report the uncertainty in the 
cost per QALY gained over a single year.
Statistical analysis
The analysis was run in R, using R Studio with the 
R package ﬂ uEvidenceSynthesis. Plots were drawn using 
Mathematica version 10.3.0.0.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. KEA, MB, JP-G, EvL, RP, and MR 
had access to the raw data. The corresponding author 
had full access to all of the data in the study and the ﬁ nal 
responsibility for the decision to submit for publication.
Results
As a universal paediatric programme expands to older 
ages (ie, from preschool age [2–4 years] to primary age 
[children commencing the school year aged 5–10 years] 
to secondary age [adolescents commencing the school 
year aged 11–15 years]), the number of cases of inﬂ uenza 
averted by an elderly or high-risk vaccination programme 
diminishes (ﬁ gure 1). Importantly, however, as the 
paediatric programme expands, and there are concurrent 
drops in inﬂ uenza incidence in the elderly and high-risk 
populations, the speed at which the paediatric programme 
is implemented becomes important. A rapid imple-
mentation each year of any vaccination programme 
of preschool, primary school, and secondary school 
children, even in the absence of an elderly vaccine 
programme, would avert a similar number of cases as 
the same paediatric programme implemented gradually 
over the inﬂ uenza season in the presence of an elderly 
programme.
Because of the high morbidity and mortality in the 
high-risk group, vaccination of these individuals remains 
cost-eﬀ ective in the presence of all paediatric strategies 
For the R package 
fluEvidenceSynthesis see 
https://github.com/MJomaba/
flu-evidence-synthesis
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with an ICER of less than £15 000 per QALY gained for 
all simulations (ﬁ gure 2). By contrast, the presence of 
paediatric vaccination produces a qualitative shift in the 
ICER for low-risk elderly vaccination.
Under the 70% vaccine coverage base case, we ﬁ nd that 
although low-risk elderly vaccination is likely to maintain 
an ICER of less than £30 000 per QALY (83% of 
simulations), the ICER itself has increased by £9982 per 
QALY relative to no paediatric programme. Compared 
with no paediatric programme, the low-risk elderly 
programme has a much higher chance of falling between 
£20 000 per QALY and £30 000 per QALY (29%, compared 
with 12%) or more than £30 000 per QALY (17%, compared 
with 1%; ﬁ gure 2). Conversely, with a cost-eﬀ ectiveness 
threshold of £15 000 per QALY, the elderly programme is 
no longer cost-eﬀ ective, with a mean ICER of £22 000 per 
QALY, and 80% of simulations providing ICER estimates 
of greater than £15 000 per QALY.
To assess the eﬀ ect of paediatric uptake speed, we 
calculated the cost-eﬀ ectiveness of elderly vaccination 
under a possible scenario in which the target coverage 
(70% vaccine uptake) was reached by the beginning 
of November (ﬁ gure 2) compared with the present 
scenario, in which school-based administration 
increases gradually from October through December; 
achievement of the target coverage earlier (ie, by the 
beginning of November) resulted in a reduction in the 
cost-eﬀ ectiveness of elderly vaccination and an increase 
in the ICER by £479 per QALY.
Our model suggests that changing the cost-
eﬀ ectiveness threshold across a reasonable range 
determines whether the low-risk elderly vaccination 
remains cost-eﬀ ective. For example, even under 
optimistic conditions of fast delivery by the beginning 
of November and a coverage of 90% for the 2–16 years 
paediatric programme, the probability that elderly 
vaccination is cost-eﬀ ective at £30 000 per QALY is still 
68%. However, if the cost-eﬀ ectiveness threshold falls 
to £15 000 per QALY under likely base case conditions, 
the elderly programme will cease to be cost-eﬀ ective, 
with only 5% of simulations falling below the threshold 
(ﬁ gure 2).
We also assessed the eﬀ ect of a reduced whole-season 
direct eﬀ ectiveness of LAIV relative to the IIV that is 
currently given to elderly and high-risk individuals 
(ﬁ gure 3). Under base case assumptions, the probability 
that the elderly programme is cost-eﬀ ective increases as 
the whole-season LAIV direct eﬀ ectiveness decreases. 
Under the conservative threshold of £15 000 per QALY, 
reducing LAIV eﬀ ectiveness to half of IIV eﬀ ectiveness 
increases the probability that the elderly programme is 
cost-eﬀ ective from 42% to 65%.
Discussion
We used a previously described calibrated mathematical 
model of seasonal inﬂ uenza transmission in England 
and Wales to assess the likely epidemiological and 
economic eﬀ ect of a paediatric programme, which is 
currently being rolled out across England, on the existing 
seasonal inﬂ uenza vaccine programme. We found that 
under reasonable assumptions of vaccine coverage 
achieved in the pilot schemes, uncertainty exists about 
the continuing cost-eﬀ ectiveness of the low-risk elderly 
vaccination programme that is available to all individuals 
with no underlying chronic disorders. The uncertainty 
surrounding these results stems primarily from 
the cost-eﬀ ectiveness threshold assumed. We found 
that vaccinating high-risk individuals was always 
cost-eﬀ ective.
Our analysis shows the potentially large eﬀ ect of 
additional vaccination programmes on the cost-
eﬀ ectiveness of existing schemes. Particularly, the 
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Figure 1: Eﬀ ect of low-risk elderly and high-risk vaccination programmes in the presence of paediatric vaccination administered at diﬀ erent speeds through the inﬂ uenza season
Preschool are children aged 2–4 years, primary are children aged 5–10 years, and secondary are adolescents aged 11–16 years. The paediatric vaccination uptake speeds are associated with the 
accumulation of the ﬁ xed paediatric vaccine coverage across October, November, December, and January.
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analysis highlights the importance of the assessment of 
existing inﬂ uenza vaccination policies in the presence of 
increased herd protection after paediatric vaccination. 
Although our results suggest that vaccinating high-risk 
individuals will always be cost-eﬀ ective over all plausible 
outcomes of the paediatric vaccination programme, the 
decision to maintain low-risk elderly vaccination is not so 
straightforward. As the new paediatric programme in 
England and Wales increases its scope from preschool-age 
children only to also include school-age children, with 
uptake consistent with other school-based programmes, 
signiﬁ cant uncertainty will probably arise concerning 
the cost-eﬀ ectiveness of a low-risk elderly vaccination 
programme. Our analysis suggests three important 
questions for policy makers in countries wishing to 
introduce a paediatric programme (panel).
In England, the LAIV school-based pilot programme 
aimed at children aged 5–10 years reached a coverage of 
52% in the ﬁ rst season of introduction and 57% in the 
second.18 However, national school-based administration 
of vaccines usually reaches much higher coverage. For 
example, at present, the ﬁ rst dose uptake for the human 
papillomavirus vaccine in England for girls aged 
12–13 years is 89%,22 and for the 3-in-1 Tetanus-Diphtheria-
Polio in Scotland for students aged 15–16 years is 88%.22,23 
Although the human papillomavirus and 3-in-1 vaccines 
are usually administered through the entire school year, 
inﬂ uenza vaccines must achieve the target coverage in a 
short timeframe, typically before the Christmas holidays. 
As such, once the LAIV programme is established, a 
school-based administration of LAIV will probably 
achieve much higher coverage than the coverage that 
exists at present, but not as high as the coverage achieved 
by other school-administered vaccines. Unlike the 
timings for preschool, elderly, and high-risk vaccine 
administration, which are patient-led, the timing for 
a school-based vaccine administration would be 
determined by the regional National Health Service 
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administered at speeds consistent with those reported during the full rollout of preschool or the pilot rollout of school-age children. (B) All paediatric vaccination 
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height, whereas each distribution represents an area of one unit. The mean (solid), 75% (dashed), and 90% (dotted) quantiles are shown to indicate in which 
cost-eﬀ ectiveness region the mean of the distribution, 75%, or 90% of its simulations lie. QALY=quality-adjusted life-year.
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(NHS) commissioner, and is limited by the capacity of 
the providers, the number of schools, and the available 
days in the school term. If maximum uptakes are to be 
reached before November, additional resources would 
probably need to be diverted to enable suﬃ  cient 
local vaccination teams. Allocation of extra resources to 
regional NHS groups responsible for school-based 
vaccine administration might result in an increase in 
either the speed at which maximum coverage is met or 
the total vaccine uptake. Our results suggest that rapid 
administration of paediatric vaccines will provide 
substantial protection to both children and adults. This 
result is consistent with research7,8 suggesting that 
inﬂ uenza transmission is driven in most seasons by the 
young. In this analysis, we assess national vaccination 
policies; however, diﬀ erences in vaccine uptake, speed of 
administration, and the population age distribution 
across NHS regions will probably result in heterogeneity 
in herd protection levels reached.
If the same number of LAIV doses were purchased, 
administration of them by the end of October would 
prevent the need for the entire low-risk elderly vaccine 
programme (ﬁ gure 1). Because children and adolescents 
are known to be drivers of inﬂ uenza transmission6–8 and, as 
such, are targeted for vaccination, cost-eﬀ ective vaccination 
depends not only on the target population, but also on the 
speed at which the population is targeted.24
The US Advisory Committee on Immunization 
Practices temporarily withdrew their recommendation 
for LAIV administration on the basis of evidence from 
the USA for ineﬃ  cacy of the vaccine, by contrast with 
other settings such as the UK.25 Calculation of the 
season-wide direct eﬀ ectiveness of LAIV is problematic 
for several reasons: ﬁ rst, the direct eﬀ ectiveness is known 
to change with age of recipient, number of vaccine doses 
(eg, two doses in the USA vs one in the UK), and endpoint 
measured (eg, virologically conﬁ rmed or syndromic 
presentation only); and second, seasonal ﬂ uctuations 
exist in the eﬃ  cacy of the vaccine due to strain 
composition of the vaccine, frequency of circulating 
strains, and vaccine manufacture. Our sensitivity analysis 
assesses the likely eﬀ ect of variation in the season-wide 
direct eﬀ ectiveness. Because of the wide variation in 
empirical estimates for direct vaccine eﬀ ectiveness, 
particularly between A and B strains, the extent to which 
LAIV eﬃ  cacy diﬀ ers from IIV remains unclear.
Quantifying the population-level eﬀ ect of a paediatric 
vaccination programme relies on capturing the social 
mixing patterns that facilitate disease transmission. 
Although this study uses empirical data on contact 
patterns from the same time period as the clinical data 
to which the model is calibrated, the methodology has 
some important caveats. For example, how the risk of 
inﬂ uenza infection varies with the number of social 
contacts relative to their type or duration (eg, familial 
relationships in the same household, workplace 
meetings, etc) is not generally not well understood; 
additionally, how behaviour changes as a result of 
infection, and the implications for disease transmission, 
are also uncertain. Through consideration of the 
empirical-derived contact patterns that are used in the 
model as prior information, which updates to reﬂ ect 
other sources of data during the model calibration 
procedure, the dependency of the model on these data 
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Figure 3: Eﬀ ect of the whole-season direct eﬀ ectiveness of live attenuated inﬂ uenza vaccine on the probability 
that the elderly vaccination programme is cost-eﬀ ective
Preschool are children aged 2–4 years, primary are children aged 5–10 years, and secondary are adolescents aged 
11–16 years. Paediatric vaccination coverage is set at 70% and is reached at speeds consistent with those observed 
during the full rollout of preschool and the pilot rollout of school-age children. Three diﬀ erent incremental 
cost-eﬀ ectiveness ratio thresholds are considered: £30 000 per QALY (red; cost-eﬀ ective), £20 000 per QALY 
(blue; very cost-eﬀ ective under current protocol), and £15 000 per QALY (green; cost-eﬀ ective under proposed 
protocol). A relative direct eﬀ ectiveness of 1 corresponds to the LAIV having the same whole-season direct 
eﬀ ectiveness as the IIV (base case value), and a relative direct eﬀ ectiveness of 0 corresponds to the LAIV having no 
eﬀ ect on inﬂ uenza epidemiology and is therefore equivalent to the cost-eﬀ ectiveness of the elderly programme 
with no paediatric coverage. LAIV=live attenuated inﬂ uenza vaccine. QALY=quality-adjusted life-year. 
IIV=inactivated inﬂ uenza vaccine.
Panel: Policy considerations for countries wishing to introduce a paediatric inﬂ uenza 
vaccination programme
We reassess the cost-eﬀ ectiveness of the elderly vaccination policy in England because it 
was one of the ﬁ rst countries to introduce a publicly funded programme of paediatric 
inﬂ uenza vaccination. With results suggesting that this is a highly cost-eﬀ ective health 
policy, other countries will probably also follow a similar route. We would therefore 
recommend that decision makers consider the following three questions before adapting 
and renegotiating their inﬂ uenza vaccination policies:
1 Are they willing to pay the same per vaccine dose for an elderly inﬂ uenza vaccination 
programme in the presence of a national paediatric programme? In our base case 
scenario in the English context, the mean incremental cost-eﬀ ectiveness increases from 
£12 552 per quality-adjusted life-year (QALY) to £29 145 per QALY after a successful 
preschool-based and school-based programme is introduced with high coverage.
2 How quickly would the vaccines be available and administered via a preschool-based and 
school-based programme? Our results show that swift paediatric vaccination can negate 
the requirement for elderly vaccination, whereas slow uptake wastes vaccine doses by 
protecting children too late to have any eﬀ ect on the reduction of transmission.
3 Would a focus on the achievement of a high coverage across all paediatric groups be 
more cost-eﬀ ective than maintaining a historically low elderly coverage? When 
combined with previous results, we conclude that the per dose cost-eﬀ ectiveness of a 
paediatric (2–16 years) vaccine is higher than that for an elderly vaccine, such that 
expansion of the paediatric programme as much as possible will always be 
economically advisable. 
Articles
www.thelancet.com/public-health   Vol 2   February 2017 e80
can be reduced. The accuracy of the model predictions 
are also contingent on the disease burden data to which 
the model is calibrated. Although the modelling 
approach is able to convey uncertainty in the predictions, 
robust age-speciﬁ c inﬂ uenza surveillance information is 
key for accurate model predictions.
With substantial uncertainty around the cost-eﬀ ectiveness 
of an elderly vaccination in the presence of a paediatric 
programme in England, other developed countries with a 
large fraction of the population older than 65 years might 
wish to reassess their funded elderly programme. In 2014, 
9·5 million individuals were older than 65 years in England, 
17·6% of the total population and the same number of 
those aged 2–16 years.26 Assuming an elderly vaccine 
uptake of 70% and a dose and administration cost of about 
£16 per vaccine, discontinuing elderly vaccination would 
save more than £106 million annually.
Most developed countries have an ageing population 
as a result of a decreasing birth rate and an increasing 
life expectancy. These demographic shifts will not only 
increase the scale of an age-targeted programme, but 
they will also aﬀ ect their cost-eﬀ ectiveness through 
changes in age-speciﬁ c social mixing patterns that 
aﬀ ect the level of herd protection accrued. Frequent 
reassessment of policy decisions is essential to ensure 
these changes are accounted for.
The evidence needed to withdraw a funded vaccine 
programme might be diﬀ erent to that needed to initiate 
one. Should a decision be under consideration to remove a 
long-standing vaccination programme as a result of 
improved public health measures elsewhere, it might be 
wise to oﬀ er a scaled-back programme rather than 
completely remove an established policy. How such a 
scaled-back programme would be implemented depends 
on the details of the at-risk groups. For example, 55% of the 
high-risk population are themselves older than 65 years. 
Alternatively, extenuating circumstances might exist that 
take precedent over low probabilities of cost-eﬀ ectiveness. 
Moreover, our results suggest that in countries that 
currently have no funded inﬂ uenza vaccination programme 
in place, it is necessary to consider a suite of age-group and 
risk-group based strategies concurrently to optimise any 
national inﬂ uenza programme.
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